BACKGROUND Till now, pooled data about the safety and efficacy of different direct-acting antiviral(DAAs) regimens in different renal situations are still under evaluation. AIM To evaluate a real-life experience of the efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r plus RIB) in patients with end-stage kidney disease (ESKD). PATIENTS AND METHODS Between January 2017 and January 2018, an open-label multicenter ... إقراء المزيد